AAMU
ENTA icon

Amundi Asset Management US’s Enanta Pharmaceuticals ENTA Stock Holding History

Amundi Asset Management US’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,727
Closed -$720K – 1508
2020
Q3 		$720K Buy
+15,727
New +$762K ﹤0.01% 1214

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Amundi Asset Management US's ENTA Position: Q4 2020 in Review

Amundi Asset Management US sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 15,727 shares — an estimated $720K sold.

Amundi Asset Management US first reported a position in ENTA in Q3 2020 and held it in 1 quarter. The position peaked at $720K in Q3 2020. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Amundi Asset Management US reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 15,727 Enanta Pharmaceuticals shares in Q4 2020, an estimated $720K.
  • Amundi Asset Management US first reported a position in Enanta Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Amundi Asset Management US's Enanta Pharmaceuticals position peaked at $720K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Amundi Asset Management US's 13F filing for Q4 2020, filed 16 Feb 2021.